Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
MAINZ, Germany, March 07, 2017 -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 – 5 in Washington, DC. This is the first example of a clinically applied systemic mRNA-based cancer immunotherapy.
| Permanent Abstract Number: CT034 | |||
| Poster: | “A First-in-Human Phase I/II Clinical Trial Assessing Novel mRNA-lipoplex Nanoparticles for | ||
| Potent Melanoma Immunotherapy” | |||
| Date: | Monday, April 3, 2017 | ||
| Session: | PO.CT01 - Phase I Clinical Trials in Progress | ||
| Time: | 8:00AM – 12:00PM Eastern Daylight Time | ||
| Location: | Poster Section 33 | ||
The Phase I/II dose escalation Lipo-MERIT trial (NCT02410733) in melanoma patients assesses the safety and tolerability as well as the potency of inducing antigen-specific immune responses of the first systemic mRNA vaccine to be developed based on BioNTech’s mRNA nanoparticle immunotherapy platform.
About BioNTech AG
BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.
More information about BioNTech is available at www.biontech.de.
For meeting requests or further information, please contact: General Inquiries: BioNTech AG Regina Jehle Tel: +49 6131 9084 1273 Email: [email protected] US Media & Investors: ICR Healthcare James Heins / Stephanie Carrington Tel: +1 203 682 8251 Tel: +1 646 277 1282 Email: [email protected] Email: [email protected] International Media & Investor Inquiries: akampion Dr. Ludger Wess / Ines-Regina Buth Tel: +49 40 8816 5964 Tel: +49 30 2363 2768 Email: [email protected]
